Web29 ago 2024 · JBCRG-M06 : First Posted: August 29, 2024 Key Record Dates: Last Update Posted: September 21, 2024 Last Verified: September 2024 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No: Layout table for additional information; Studies a U.S. FDA ... WebModulo Wi-Fi RT5370N M08-50 antenna integrata. Modulo Wi-Fi 802.11 b/g/n funzionante a 2,4 GHZ e basato sul chipset Ralink RT5370. Particolarmente adatto per essere utilizzato con i moduli Raspberry Pi, dispone di antenna su PCB, potenza di trasmissione 17dBm, sensibilità di ricezione -84dBm @ 11 Mbps, sicurezza: WEP 64/128, WPA, WPA2, …
ESMO Asia Virtual Congress 2024 OncologyPRO
Web14 dic 2024 · JBCRG-M08(AMBER trial) Basic Information. Recruitment status: Recruiting: Health condition(s) or Problem(s) studied: Hormone receptor-positive, HER2-negative … WebFinally, among 389 patients who were enrolled in JBCRG-01, JBCRG-02, and JBCRG-03, 353 patients were included in the present study. The detailed patients’ characteristics have been summarized in the previous articles [13, 14]. In brief, 200 patients received adjuvant endocrine therapy according to protocol and practice guidelines, and after the thorpe spa
CREATE-X a role for capecitabine in early-stage breast cancer: an ...
Web25 mar 2024 · Purpose To investigate clinical usefulness of eribulin-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients. Methods Patients in group A (aged < 65 years with homologous recombination deficiency, HRD, score ≥ 42, or those at any age with germline BRCA mutation, gBRCAm) were randomized to 4 cycles of … Web8 giu 2024 · Cite this article. Yamashita, T., Masuda, N., Saji, S. et al. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, … Web7 mag 2024 · Trastuzumab (Tmab), pertuzumab (Pmab), and taxane has been a standard first-line treatment for recurrent or metastatic human epidermal growth factor (HER2)-positive breast cancer (HER2+ mBC) but has some safety issues due to taxane-induced toxicities. This has led to ongoing efforts to seek less toxic alternatives to taxanes that … thorpes organic family farm east aurora